RecruitingNCT05891379
Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders
Studying Neuromyelitis optica spectrum disorder
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Xuanwu Hospital, Beijing
- Principal Investigator
- Junwei Hao, MDXuanwu Hospital, Beijing
- Intervention
- Inebilizumab(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2025
Study locations (1)
- Xuanwu Hospital, Capital Medical University, Beijing, Beijing Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05891379 on ClinicalTrials.govOther trials for Neuromyelitis optica spectrum disorder
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07377305Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)Tang-Du Hospital
- RECRUITINGNCT05004493Biorepository and Registry for Plasma Exchange PatientsCharles M Knudson
- RECRUITINGNCT04106830Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)Beijing Tiantan Hospital
- ACTIVE NOT RECRUITINGNCT01623076The Longitudinal CONQUER Study of Rare Neuroimmunologic DisordersUniversity of Texas Southwestern Medical Center